Memphasys (ASX:MEM)

Executive Summary

Memphasys Ltd (ASX:MEM) is an Australian MedTech company specializing in reproductive biotechnology, addressing a critical need in assisted reproduction. Leveraging its proprietary electrophoretic membrane technology, the company has developed two key products: the Felix™ sperm-separation system, which enables rapid, high-quality sperm selection, and the RoXsta™ oxidative-stress diagnostic platform for point-of-care assessment of oxidative stress in semen samples. These innovations target both human IVF clinics and livestock breeding operations, offering improved outcomes in fertility treatments. Founded in 2020 and headquartered in Sydney, Memphasys has raised approximately A$30 million and operates at a commercial stage with 50-200 employees. The company’s dual focus on human and animal markets diversifies revenue streams and positions it for growth in the global fertility sector. Memphasys is currently pursuing commercial expansion, with initial sales of Felix being generated in Australia and select international markets. The company is actively seeking regulatory approvals for the RoXsta diagnostic platform, which could open larger markets in the US and Europe. With a growing pipeline of clinical validation studies and ongoing discussions with potential distribution partners, Memphasys is poised to capture market share in the fragmented fertility technology space. However, competition from established players and the need for broader clinical adoption remain key risks. The company’s near-term outlook hinges on successful commercialization and eventual profitability, supported by its innovative product suite and strategic market positioning.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) clearance for RoXsta oxidative-stress diagnostic platform60% success
• Q3 2026Exclusive distribution agreement for Felix™ with a major US IVF network40% success
• Q3 2026Positive clinical study results for Felix™ in large animal breeding (bovine)70% success